News & Updates
Filter by Specialty:
Baricitinib delays, lowers frequency of flares in JIA
In patients with juvenile idiopathic arthritis (JIA) with insufficient response to conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs), the JAK*1/2 selective inhibitor baricitinib reduced the frequency and delayed time to disease flares, according to a phase III trial presented at EULAR 2022.
Baricitinib delays, lowers frequency of flares in JIA
23 Jun 2022
SGLT2is reduce serious hyperkalaemia risk in T2D, CKD patients
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) consistently reduced the risk of serious hyperkalaemia (serum potassium [K+] ≥6.0 mmol/L) without increasing the risk of hypokalaemia (serum K+ ≤3.5 mmol/L) in individuals with type 2 diabetes (T2D) at high cardiovascular (CV) risk, or in those with chronic kidney disease (CKD), a meta-analysis has shown.
SGLT2is reduce serious hyperkalaemia risk in T2D, CKD patients
23 Jun 2022
Upadacitinib for atopic dermatitis may trigger mild, moderate acne
Upadacitinib treatment for atopic dermatitis (AD) may cause acne as a side effect, though this is usually only mild or moderate in severity and can be managed by topical intervention, reports a recent study.
Upadacitinib for atopic dermatitis may trigger mild, moderate acne
23 Jun 2022
Aminosalicylate use more common among older than younger IBD patients
Use of medication is markedly different among older patients with inflammatory bowel disease (IBD), with more aminosalicylate monotherapy and less antitumour necrosis factor monotherapy than younger patients, according to a US study.
Aminosalicylate use more common among older than younger IBD patients
22 Jun 2022
Lutein/zeaxanthin an appropriate substitute for beta carotene in AREDS2
Supplementation with lutein/zeaxanthin instead of beta carotene is safe and does not contribute to an increase in lung cancer risk while having a potential beneficial effect on the risk of progression to late age-related macular degeneration (AMD), according to data from the Age-Related Eye Disease Study 2 (AREDS2) study.
Lutein/zeaxanthin an appropriate substitute for beta carotene in AREDS2
21 Jun 2022
Nintedanib falls short in bladder cancer trial
In the phase II NEOBLADE* trial, the addition of the multikinase** inhibitor nintedanib to neoadjuvant chemotherapy (CT) consisting of gemcitabine and cisplatin failed to improve pathological complete response (pCR) and progression-free survival (PFS) in individuals with locally advanced muscle-invasive bladder cancer (MIBC).
Nintedanib falls short in bladder cancer trial
21 Jun 2022
Ceritinib shows therapeutic potential in ALK-positive nonsmall cell lung cancer
The anaplastic lymphoma kinase (ALK) inhibitor ceritinib delivers favourable antitumour activity in ALK-mutated nonsmall cell lung cancer (NSCLC) patients with active brain metastases and/or leptomeningeal disease, according to the phase II ASCEND-7 trial.
